Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast.
Shares of DXCM rose 1% to $65.70 apiece in post-market trading today.
The San Diego-based continuous glucose monitor (CGM) maker reported profits of $267.3 million. That equals 68¢ per share on sales of $1.259 billion for the three months ended Dec. 31, 2025.
Dexcom recorded a 76.2% bottom-line gain on a sales increase of 13.1%.
The company’s non-GAAP EPS, also 68¢, landed 3¢ ahead of expectations on Wall Street. Sales narrowly topped projections, as experts forecast $1.25 billion in revenue.
Highlights in the quarter include the launch of the Dexcom G7 15 Day, the company’s longest-wear CGM offering. That launch also included insulin delivery pairings with Insulet and Beta Bionics. The company also won FDA clearance for its smart CGM-integrated basal dosing optimizer.
“2025 was another great year for Dexcom as we significantly expanded access to Dexcom CGM and launched our Dexcom G7 15 Day system,” said Jake Leach, president and CEO. Leach officially took over as permanent CEO on Jan. 1, following an interim stint. “We look forward to building on this momentum in 2026 as we work to deliver improved health outcomes for many more people globally.”
Dexcom reiterated its 2026 guidance for revenue between $5.16 billion and $5.25 billion. That would mark growth between approximately 11% and 13%. The company forecasts non-GAAP gross profit margin to land between 63% and 64%.
The analysts’ take on Dexcom
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintain a “Buy” rating for Dexcom after the earnings report.
The analysts note that the full year delivered a record for new patient starts. A record in 2026 would have to come in at the top end of the company’s range for 2026, though.
Leach outlined the emphasis of the G7 15 Day rollout and new software offerings, the analysts say. He also outlined an effort to increase focus outside the U.S. The analysts say Leach suggested that OUS could become a larger business than the core U.S. market over the long-term.
Additionally, the company expects CMS to propose coverage expansion into the type 2 diabetes non-insulin patient population during the first half of the year.
“We like all the efforts to add new enhancements and explore markets outside the U.S. but we most want to see patient/prescriber demand continue to improve in the U.S. this year,” the analysts concluded.
